Mureva Announces FDA De Novo Authorization and Peer-Reviewed Publication of Pivotal Mureva OM Trial
American Medical Association Establishes Category III CPT Code for Procedure Associated with the Use of MuReva Phototherapy’s LED-based Photobiomodulation Therapy Device
Mureva Announces FDA De Novo Authorization and Peer-Reviewed Publication of Pivotal Mureva OM Trial
American Medical Association Establishes Category III CPT Code for Procedure Associated with the Use of MuReva Phototherapy’s LED-based Photobiomodulation Therapy Device
Mureva Announces FDA De Novo Authorization and Peer-Reviewed Publication of Pivotal Mureva OM Trial
American Medical Association Establishes Category III CPT Code for Procedure Associated with the Use of MuReva Phototherapy’s LED-based Photobiomodulation Therapy Device
Mureva Announces FDA De Novo Authorization and Peer-Reviewed Publication of Pivotal Mureva OM Trial
American Medical Association Establishes Category III CPT Code for Procedure Associated with the Use of MuReva Phototherapy’s LED-based Photobiomodulation Therapy Device
MuReva Phototherapy Presents Data during 2025 ASTRO Meeting Confirming Safety and Efficacy of the Company’s LED-based Photobiomodulation Therapy Device
Mureva Announces FDA De Novo Authorization and Peer-Reviewed Publication of Pivotal Mureva OM Trial
American Medical Association Establishes Category III CPT Code for Procedure Associated with the Use of MuReva Phototherapy’s LED-based Photobiomodulation Therapy Device
MuReva Phototherapy Presents Data during 2025 ASTRO Meeting Confirming Safety and Efficacy of the Company’s LED-based Photobiomodulation Therapy Device
Mureva Announces FDA De Novo Authorization and Peer-Reviewed Publication of Pivotal Mureva OM Trial
American Medical Association Establishes Category III CPT Code for Procedure Associated with the Use of MuReva Phototherapy’s LED-based Photobiomodulation Therapy Device
Mureva Announces FDA De Novo Authorization and Peer-Reviewed Publication of Pivotal Mureva OM Trial
American Medical Association Establishes Category III CPT Code for Procedure Associated with the Use of MuReva Phototherapy’s LED-based Photobiomodulation Therapy Device
Mureva Announces FDA De Novo Authorization and Peer-Reviewed Publication of Pivotal Mureva OM Trial
American Medical Association Establishes Category III CPT Code for Procedure Associated with the Use of MuReva Phototherapy’s LED-based Photobiomodulation Therapy Device
Mureva Announces FDA De Novo Authorization and Peer-Reviewed Publication of Pivotal Mureva OM Trial
American Medical Association Establishes Category III CPT Code for Procedure Associated with the Use of MuReva Phototherapy’s LED-based Photobiomodulation Therapy Device
Mureva Announces FDA De Novo Authorization and Peer-Reviewed Publication of Pivotal Mureva OM Trial
American Medical Association Establishes Category III CPT Code for Procedure Associated with the Use of MuReva Phototherapy’s LED-based Photobiomodulation Therapy Device
“Through many studies and systematic reviews, PBM has demonstrated efficacy in preventing the incidence and severity of OM in patients receiving radiation therapy for head and neck cancers. For a company like MuReva to [produce] a really rigorously engineered device that’s really simple to use and train a center on: that’s what’s needed for the field.”
“We saw a patient that was enrolled in the PBM trial who was very concerned of developing painful mouth sores from OM and did not because of the Mureva device. The patient was crying because of happiness, because he didn’t have any mouth sores or any pain. To me, that’s success.“
“The benefit to using Mureva PBM is significant in the reduction of oral mucositis for patients undergoing head and neck cancer therapy. They do better, they have less pain, less mucositis, and overall feel better.”
“Through many studies and systematic reviews, PBM has demonstrated efficacy in preventing the incidence and severity of OM in patients receiving radiation therapy for head and neck cancers. For a company like MuReva to [produce] a really rigorously engineered device that’s really simple to use and train a center on: that’s what’s needed for the field.”
“We saw a patient that was enrolled in the PBM trial who was very concerned of developing painful mouth sores from OM and did not because of the Mureva device. The patient was crying because of happiness, because he didn’t have any mouth sores or any pain. To me, that’s success.“
“The benefit to using Mureva PBM is significant in the reduction of oral mucositis for patients undergoing head and neck cancer therapy. They do better, they have less pain, less mucositis, and overall feel better.”
“Through many studies and systematic reviews, PBM has demonstrated efficacy in preventing the incidence and severity of OM in patients receiving radiation therapy for head and neck cancers. For a company like MuReva to [produce] a really rigorously engineered device that’s really simple to use and train a center on: that’s what’s needed for the field.”
“We saw a patient that was enrolled in the PBM trial who was very concerned of developing painful mouth sores from OM and did not because of the Mureva device. The patient was crying because of happiness, because he didn’t have any mouth sores or any pain. To me, that’s success.“
“The benefit to using Mureva PBM is significant in the reduction of oral mucositis for patients undergoing head and neck cancer therapy. They do better, they have less pain, less mucositis, and overall feel better.”
“Through many studies and systematic reviews, PBM has demonstrated efficacy in preventing the incidence and severity of OM in patients receiving radiation therapy for head and neck cancers. For a company like MuReva to [produce] a really rigorously engineered device that’s really simple to use and train a center on: that’s what’s needed for the field.”
“We saw a patient that was enrolled in the PBM trial who was very concerned of developing painful mouth sores from OM and did not because of the Mureva device. The patient was crying because of happiness, because he didn’t have any mouth sores or any pain. To me, that’s success.“
“The benefit to using Mureva PBM is significant in the reduction of oral mucositis for patients undergoing head and neck cancer therapy. They do better, they have less pain, less mucositis, and overall feel better.”
“Through many studies and systematic reviews, PBM has demonstrated efficacy in preventing the incidence and severity of OM in patients receiving radiation therapy for head and neck cancers. For a company like MuReva to [produce] a really rigorously engineered device that’s really simple to use and train a center on: that’s what’s needed for the field.”
“We saw a patient that was enrolled in the PBM trial who was very concerned of developing painful mouth sores from OM and did not because of the Mureva device. The patient was crying because of happiness, because he didn’t have any mouth sores or any pain. To me, that’s success.“
“The benefit to using Mureva PBM is significant in the reduction of oral mucositis for patients undergoing head and neck cancer therapy. They do better, they have less pain, less mucositis, and overall feel better.”
“Through many studies and systematic reviews, PBM has demonstrated efficacy in preventing the incidence and severity of OM in patients receiving radiation therapy for head and neck cancers. For a company like MuReva to [produce] a really rigorously engineered device that’s really simple to use and train a center on: that’s what’s needed for the field.”
“We saw a patient that was enrolled in the PBM trial who was very concerned of developing painful mouth sores from OM and did not because of the Mureva device. The patient was crying because of happiness, because he didn’t have any mouth sores or any pain. To me, that’s success.“
“The benefit to using Mureva PBM is significant in the reduction of oral mucositis for patients undergoing head and neck cancer therapy. They do better, they have less pain, less mucositis, and overall feel better.”
“Through many studies and systematic reviews, PBM has demonstrated efficacy in preventing the incidence and severity of OM in patients receiving radiation therapy for head and neck cancers. For a company like MuReva to [produce] a really rigorously engineered device that’s really simple to use and train a center on: that’s what’s needed for the field.”
Nathaniel Simon Treister, DMD
“We saw a patient that was enrolled in the PBM trial who was very concerned of developing painful mouth sores from OM and did not because of the Mureva device. The patient was crying because of happiness, because he didn’t have any mouth sores or any pain. To me, that’s success.“
Alessandro Villa, DDS, PhD, MPH
“The benefit to using Mureva PBM is significant in the reduction of oral mucositis for patients undergoing head and neck cancer therapy. They do better, they have less pain, less mucositis, and overall feel better.”
Jennifer Frustino, DDS, PhD, MS
“Through many studies and systematic reviews, PBM has demonstrated efficacy in preventing the incidence and severity of OM in patients receiving radiation therapy for head and neck cancers. For a company like MuReva to [produce] a really rigorously engineered device that’s really simple to use and train a center on: that’s what’s needed for the field.”
“We saw a patient that was enrolled in the PBM trial who was very concerned of developing painful mouth sores from OM and did not because of the Mureva device. The patient was crying because of happiness, because he didn’t have any mouth sores or any pain. To me, that’s success.“
“The benefit to using Mureva PBM is significant in the reduction of oral mucositis for patients undergoing head and neck cancer therapy. They do better, they have less pain, less mucositis, and overall feel better.”
